We are delighted to share with you that China’s leading research and innovation cluster will use WuXi NextCODE technology to advance precision medicine. We have partnered with Fudan University to bring WuXi NextCODE’s world-leading population human genomics database system and integrated research and clinical solutions to the Fudan-led Collaborative Innovation Center of Genetics and Development (CICGD) as an enterprise partner. The partnership will empower CICGD scientists to perform gene sequencing and bioinformatics analysis with unparalleled speed and precision, thereby accelerating research, clinical diagnosis, and treatment of rare inherited diseases and malignant tumors.
The CICGD brings together several other world-renowned Chinese research institutions, including Shanghai Jiaotong University, Nanjing University, Zhongshan University, Central South University, the Shanghai Institutes for Biological Sciences, the Institute of Genetics and Developmental Biology, and the Beijing Institute of Genomics. Collectively, these institutions are dedicated to researching scientific questions in genetics and developmental biology as well as evaluating their impact on human health.
Already powering population-scale genomics in Iceland, the WuXi NextCODE system was yesterday the only genome analysis platform selected to provide clinical interpretation in both rare disease and cancer for the first phase of Genomics England’s 100,000 Genomes Project. The partnership announced today will bring this technology to Fudan University and turn Shanghai into a premier global innovation center for human genomics.
- Official press release
- WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in both Rare Disease and Cancer
- Big Data and Genomics Meet the Cloud: the First Unified Global Platform for Precision Medicine